Pulmonary cedema caused by alteration ofalveolocapillary permeability is a frequent complication of septic shock. Therefore, among the effects of vasoactive drugs used in the treatment of septic shock, changes in venous admixture may be of clinical importance. This study was undertaken in order to determine the effects of dopamine on gas exchange and pulmonary hmmodynamics in cases of septic shock associated with hypoxamia.
Thirteen patients were evaluated. In all cases shock was diagnosed according to standard clinical criteria, and sepsis was recognized by positive blood cultures and/or active suppuration. The decision to use dopamine was based upon the baseline hamodynamic data showing that blood pressure and cardiac index were low and systemic vascular resistance was reduced. In all patients, breathing pure oxygen for twenty minutes, Pa 02 was low and intrapulmonary shunting was increased. Sixteen procedures were performed on thirteen patients. In all patients cardiac output was measured by the thermodilution technique according to Swan and Ganz. The same catheter was used for determination of pulmonary artery pressure and pulmonary wedge pressure. All the measurements were repeated 30 minutes after the Table 1 Hamodynamic changes with dopamine infusion in patients with shock (mean of 16 measurements on 13 patients) start of dopamine infusion. All patients were ventilated with a volume-controlled apparatus. Samples for gas determinations were taken while the patients were breathing pure oxygen for twenty minutes at least. Intrapulmonary shunting was calculated according to the usual formula. Table 1 shows the changes following dopamine infusion. As predicted, cardiac index significantly increases. Mean pulmonary wedge pressure does not significantly increase and pulmonary vascular resistance decreases from 4.1 to 3.5 iu. During the same time, while the patient is breathing pure oxygen, Pa 0°slightly decreases from 175 to 134 mmHg, while intrapulmonary shunting markedly increases from 27 to 40%. Oxygen content difference between arterial and mixed venous blood significantly decreases and oxygen consumption does not change.
In all cases intrapulmonary shunting increases after dopamine infusion. In some cases Pa 0, does not change, or decreases. But surprisingly enough, in several cases Pa 0°increases despite the increasing intrapulmonary shunting. The explanation of this phenomenon may be related to the increase of the mixed venous oxygen saturation, a consistent finding which was probably due to haemodynamic improvement without any change in oxygen consumption. Therefore, venous blood with more oxygen comes to the lung and thus Pa 02 increases despite the increase of intrapulmonary shunting. It is interesting to discuss why intrapulmonary shunting is increased. In order to solve this problem, patients were separated into two groups according to the pulmonary wedge pressure responses following dopamine infusion. In ten procedures, group A, pulmonary wedge pressure (PWP) did not change after dopamine infusion. On the other hand, in six procedures, group B, it increased from 13 to 17 mmHg. Pulmonary vascular resistance decreased by the same extent in both groups. Therefore, the increasing intrapulmonary shunting associated with a decrease in pulmonary vascular resistance suggests a recruitment phenomenon. Intrap -lmonary shunting was much more increased in patients of group B, in whom PWP was increased, than in the patients of group A in whom PWP remained unchanged. In other words, the increase of the cardiac index following dopamine infusion reduces the pulmonary vascular resistance and thereby increases intrapulmonary shunting, by the reopening of previously closed vessels in poorly ventilated areas. This recruitment phenomenon is much more apparent when the pulmonary wedge pressure is increased.
In 6 of the 13 patients we performed an infusion of isoprenaline for comparison. With this drug the intrapulmonary shunting did not change despite the increase of cardiac index and the decrease of the pulmonary vascular resistance (Table 2) . This unexpected discrepancy between the action of dopamine and isoprenaline on gas exchange may be explained by the decrease of pulmonary wedge pressure observed with isoprenaline.
Conclusions
(1) Dopamine infusion markedly increases preexisting intrapulmonary shunting.
(2) This phenomenon could be related to the decrease of pulmonary vascular resistance and, in some patients, to an increase in the left heart filling pressure.
(3) The harmful effect on systemic oxygenation is alleviated by the increase of the oxygen content in the mixed venous blood, because of the increased cardiac index with unchanged oxygen consumption.
DISCUSSION
Professor Doliery: I think the reason for the difference between the effects of dopamine and isoprenaline on the intrapulmonary shunting is not the one you suppose. This has been described before with isoprenaline and I think the explanation is simply that isoprenaline stimulates ventilation. There is increased ventilation. I think that is the reason: the improvement in ventilation neutralizes any change there may be in opening up the perfusion of poorly ventilated areas. Now I do not know what effect dopamine has on ventilation, but I imagine it does not stimulate it.
Professor Rapin: I agree with Professor Dollery.
Nevertheless it should be emphasized that PaCO, does not change following isoproterenol infusion. This finding does not support the role of hyperventilation.
Mr P E Ghadiali (Brompton Hospital, London):
My remarks are restricted to the use of dopamine during heart-lung bypass for cardiac surgery. Dopamine was used when intraoperative heart failure was being treated with circulatory support and when very ill patients had to undergo openheart surgery, usually as an emergency measure.
I would like to mention very briefly our findings in a clinical situation. In small and moderate doses, there was no change in the arterial, venous and left atrial pressures suggesting and confirming that it had no effect on the peripheral vascular resistance. The systemic blood flow was constant. The inotropic action was much less than that of isoprenaline or adrenaline and no chronotropic effect could be detected. When ill patients, who were oliguric or anuric, were put on the heartlung bypass for urgent open-heart surgery and dopamine was given, they started passing urine much sooner than had been the case from our past experience. Whereas formerly it would take thirty minutes or more, with dopamine it was usually ten minutes or so before urine started to come.
Professor J B Bruckner (West Berlin): Usually if you are increasing the pressure you are increasing the myocardial oxygen demand, so you will get better perfusion but the myocardium will need more oxygen. You have to be very careful if you try to improve the situation by means of a rise in pressure alone.
Mr Ghadiali: I think that you misunderstood me. I am talking about intraoperative heart failure while the patient is on heart-lung bypass. If you run into trouble, the best way to manage this kind of situation is by decompressing the left ventricle with a vent, and lowering its pressure. At the same time, you raise the arterial pressure. If you do it by increasing the flow, fine. If you cannot do it in this way, vasopressors are used. The one I prefer is adrenaline, because not only does it have a peripheral effect but it also has a cardiotonic action. At the same time, if I find that there is considerably increased irritability of the heart, I may reduce the amount of adrenaline and use dopamine or isoprenaline. Or, if you find that all three drugs cause irritability, you can raise the blood pressure by using, for instance, metaraminol. However, as Dr Goldberg mentioned, we only like to use drugs which have a short action so that you can control the situation and withdraw them as soon as possible.
Professor Goldberg (Chairman): We have had a lot of discussion today, but I have cut people short so that we could reach this stage and I think the best thing to do would be to see if any of you have any questions for any of the speakers, and then we will ask the speaker to answer the question from the floor.
Mr Ghadiali: I have a question, but not for any specific speaker. I should like to know from people who have experience of using dopamine in the presence of hypox emia whether its action is still the same. Professor Goldberg: I do not think anyone has any specific comments. There are a number of papers in the literature which suggest that many of these drugs' actions are reduced in the presence of hypoxmmia. I am just answering in general without any specific experience. Certainly there seem to be more arrhythmias with catecholamines in the hypoxamic state. This is a general statement, but I do not know of any specific studies. I just want to make a comment about adrenaline.
Adrenaline has a very potent renal vasoconstrictor action and, although it decreases peripheral resistance, it is not the same as isoproterenol. That is, if you administer adrenaline to a normal subject there is renal vasoconstriction because the renal and skin alpha-adrenergic receptors are very sensitive to adrenaline. I do not know if you have experienced any decreased urine flow when adrenaline is used. It seems to be a favourite drug with surgeons; I do not know why. Would you care to answer that ? Mr Ghadiali: You are absolutely right, and this is why we are very careful about the amount of adrenaline we use. We use minute amounts just to get the desired effect. If the heart action improves, and cardiac action increases the urinary flow is satisfactory. If the patient's condition deteriorates and you have to keep on increasing the adrenaline, then I am afraid in our hands this is usually an irreversible situation. Dr A Miller (Chicago): Professor Goldberg, I want to complicate your life a bit. There has been no discussion about venomotor effects today. You are interested in this, and I thought that it might not be amiss at least to mention it and discuss the comparative effects of norepinephrine and other drugs.
Professor Goldberg: The question is venomotor tone. I do not have any specific measurements. Dopamine constricts the venous vascular bed -Dr Thompson mentioned thisand this may be one reason why we see some increase in atrial pressures. I do not know of any relevant data about norepinephrine. As far as I know, it is the same as dopamine: one-fiftieth as potent in the venous system as it is in the arterial system. I have no specific information.
We cut off the discussion of the neurosurgical paper a bit and I should like to discuss that further.
It was a fascinating paper and the only reason I cut it off was shortage of time. However, dopamine is beginning to be used in the United States intravenously for this condition. I do not know why or how it got started. One use that I have seen, with extremely high doseswhich was shocking to me when I saw it, not shocking as to the outcome, but just the doseswas in a normotensive patient under the care of the neurosurgeons. That patient was normotensive, but after surgery, he had a hemiparesis. They raised the blood pressure with dopamine up to about 120 to 130 diastolic, and as long as the pressure was high, the patient was able to move his limbs on this side and to talk. As soon as the pressure went down to about 90, the weakness reappeared. So they kept this infusion up for about three weeks at an extremely high dose of 30 to 40 pg. The patient was excreting a lot of urine, and he left the hospital, which meant to me that, at least in this particular patient, the drug was not toxic. I know that neurosurgeons do use drugs to raise the blood pressure hoping to improve perfusion and I was wondering whether you have any comment on that kind of use, or whether you feel that would be a suitable indication. Dr Boullin: I imagine that the effect of dopamine which you are are describing was probably an effect on the perfusion pressure per se rather than anything else. Perhaps my neurosurgical colleague, Mr Adams, might like to add a comment.
Mr C B T Adams (Oxford): This technique has been used fairly widely. We have tried it very occasionally and have not had such a dramatic effect. So we have taken this other line of attack on the problem of cerebral arterial spasm.
Dr Boullin: I wonder if I could raise a point that I wanted to raise in my paper, which is about the central effects of dopamine. I do not mean effects on cerebral blood vessels, I mean effects on the brain itself. We observed an arousal phenomenon. Dr Miller mentioned increased alertness in some of his patients -I do not know what he means by that and perhaps he could elaborateand I think that you, Dr Goldberg, mentioned vomiting. I presume that is a central effect. In any event, I think this is something we ought to consider. Certainly we must consider it from a neurosurgical viewpoint, and also people who are using high concentrations infused intravenously -I do not know what they mean by 'high concentrations', but probably in the 100 jg/kg per min rangemust consider it. I would like to hear any comments on this.
Professor Goldberg: Perhaps I can start. The CNS pharmacologists have identified what they consider to be dopamine receptors, and one of the actions they are associated with is arousal. They say that the arousal produced by amphetamines, for example, is due to release of dopamine or, possibly, noradrenaline, on to dopamine receptors. If one treats an animal the way you did, using a catheter and applying the dopamine directly to the brain, arousal is one of the things that happens. There is a lot of work going on to discover what the relevant sites are in that type of study. I have never considered it to be a very clean kind of experiment, but the neuropharmacologists do this type of thing. As far as vomiting is concerned, this can occur on either side of the blood/brain barrier because the vomiting centre is both peripheral and central. We know that L-dopa, for example, produces vomiting quite commonly. So my guess would be that the vomiting is not due to the drug crossing, but being on the blood side of the blood/ brain barrier. Certainly if dopamine is applied directly to the vomiting centre, vomiting does occur. So that both the phenomena you describe are certainly consistentwith a dopaminergic action. Dr Miller: I do not know how much material you can glean from seven patients, but a few observations were striking. The improvement in affect of response in some of the patients was striking, and both nurses and families confirmed this. We had one patient with Cheyne-Stokes respirations which disappeared with dopamine administration and on a couple of occasions the intravenous infusion infiltrated. The Cheyne-Stokes returned and when we started the infusion again, the Cheyne-Stokes disappeared. I assumed these effects were a function of improved cardiac output, and gave no thought to the possibility of direct stimulation.
Dr Boullin: I wonder if I could just tell you what we observed with our patient no. 5 when we increased the dopamine infusion rate to 200 ig/min, which we did for short periods. At the time we were infusing 10 jg/min and the patient was asleep and snoring. Then we increased the infusion rate to 200 jig/min and, within 30 seconds, the patient woke up and opened his eyes and, within one minute, he would answer questions rationally. We continued the high rate of infusion for about 5 minutes and he was very alert, you might say over-alert, during that time. Then we switched off the rapid infusion, in other words reduced it to the lower rate, and he went back to sleep within 90 seconds and was snoring again. We repeated this three times at about 20 to 30 minute intervals. It was a very dramatic effect indeed.
Professor Goldberg: Were there any changes in arterial blood pressure? I think that Professor Dollery may want to comment on this, but many of us working with the new antihypertensive agents think that they may be acting by central adrenergic receptors and so forth. Dr Boullin: No, there were no changes in arterial blood pressure or in intracranial pressure.
Dr A R Green (Oxford): Mr Chairman, you mentioned the blood/brain barrier, and of course this is generally brought up in relation to amines because they are said not to cross it. I am not sure how absolutely true this is. It was always said of serotonin that it did not cross, and in fact it has subsequently been shown that it probably does cross if it gets broken down. In our laboratory we can show in experimental animals that some amines like 5-hydroxytryptamine (5-HT), which you can inject peripherally, cannot normally be detected in the brain. But if you immediately start inhibiting monoamine oxidase to any degree at all and no one knows what the state of this enzyme is in people who are very sick anywaythen you start to find 5-HT in the brain, presumably because it has not been broken down as it enters, and it can thus start building up. So I think we cannot just assume, simply because this so-called blood/brain barrier exists, that amines will not get in under some circumstances.
Professor Goldberg: That is a very good comment. I do not know of any good studies on this, but certainly with the monoamine oxidase inhibitors we may be able to demonstrate more. There are some very specific effects produced by intracerebral L-dopa in guinea-pigs and in rats; in guinea-pigs it produces gnawing behaviour, and in the rat, stereotyped behaviour. As far as I know, this has not been replicated with parenteral administration of the drug, but maybe it has not yet been done with monoamine oxidase inhibitors and dopamine in combination. This could be checked out very simply. Of course, the rat is not man; that is why that study is so interesting.
Are there any further questions about anything? Does anyone have any questions for any of the speakers ?
Professor Dollery: This is really just a comment on Dr Boullin's paper. I wonder if he has injected xenon or crypton to measure cerebral blood flow, because with this technique he would be able to make more frequent measurements than he can do by angiography. Having spent part of nMy life measuring the calibre of retinal blood vessels on angiograms, I know how inaccurate it is as a technique, and how difficult it is to draw conclusions from fairly small changes in vessel calibre. I think that he might be much more comfortable if he were measuring cerebral blood flow.
The other thing would be that he would also, of course, be able to compare the effects of local administration with those ofsystemic administration.
Dr Boullin: The answer to Professor Dollery's question is that we have not done cerebral blood flow yet, but we propose to do it. I think Professsor Du Boulay would like to make a comment.
Professor G H Du Boulay (London): Yes, I am part of the team although I am in London. I have been measuring the calibre of arteries by angiography for a very long time. Although we did not discuss the methods here, we have a technique which gives us statistically good results. The difficulty about cerebral blood flow measurement is that it will tell you what is happening in a particular segment of the arterial tree, but it will not tell you which bit of the segment is responsible. As we have shown with our angiograms, one part of the artery may be dilating while another part is constricting. You need both techniques in order to get a full understanding of the mechanism.
Professor Goldberg: We have heard a lot of interesting papers and I have learned a lot myself. There are some things that I had simply never heard before about dopamine. I think it is a growing field. I understand that the drug is now available in Great Britain and I shall be very interested to see what is going to happen.
What came out very clearly today was the problem of dosage, and this seems to be unresolved as yet. The German workers in particular are very concerned about the upper limit, whereas Dr Thompson, at the other extreme, would go very high. We are going to have to resolve this sooner or later.
The other papers have discussed various clinical uses, and these seem to support some of the previous experimental data. I do not know if we have talked enough about adverse r&hctions; I am glad that we have at least mentioned the possible complications ofarrhythmias and peripheral ischmmia; and of course, as with any other drug, it is partly because of the side-effects that the question of dosage must be gone into very carefully.
